Banner for leaf pages 2

Cabazitaxel (Jevtana)

Also known as Jevtana

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Source: Wikipedia

What is it prescribed for?

Patients are most commonly prescribed cabazitaxel to treat blastomycosis, rabies, west nile virus, and pick disease.

Ajax-loader Loading...